Predictive biomarker of survival in the treatment of renal cell carcinoma
AssigneeAmgen Inc.
InventorsAbraham Antonio Anderson, David M. Weinreich
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor.
Claims27
A method of predicting human renal cell carcinoma (RCC) patients having an increased likelihood of obtaining clinical benefit from, and prior to treatment with, a therapeutically effective amount of a VEGFR inhibitor and an Ang2 inhibitor, the method comprising comparing a patient PLGF concentration with a PLGF concentration parameter, wherein the patient PLGF concentration lower than the PLGF concentration parameter is predictive of the increased likelihood of clinical benefit.
A method of predicting human renal cell carcinoma (RCC) patients having an increased likelihood of obtaining clinical benefit from, and prior to treatment with, a therapeutically effective amount of a VEGFR inhibitor and an Ang2 inhibitor, the method comprising stratifying, on the basis of a patient PLGF concentration, the RCC patients into at least two groups relative to a PLGF concentration parameter, wherein an RCC patient having a low patient PLGF concentration relative to the PLGF concentration parameter has an increased likelihood of obtaining the clinical benefit.
Dependencies are inferred from the claim text.